Leukemia e matla ea Lymphoblastic (T-ALL)-09

Seithuti sa univesithi se bitsoang Mengmeng se tsoang Yanjiao, Guizhou, se fumane kalafo e sebetsang ho BIOOCUS Medical Group.

Mengmeng, mosali, ea lilemo li 21, o ile a hlaha tleliniking ea rona ea bakuli ba sa keneng sepetlele ka la 22 Phuptjane 2021, a khathetse khafetsa. Teko ea kamehla ea mali e bontšitse WBC 479×10^9/L. Litlhahlobo tse ling tsa moko oa masapo li tiisitse acute lymphoblastic leukemia (T-cell subtype). O ile a etsoa chemotherapy habeli, empa leukemia e ile ea lula e sa arabele, ka MRD (lefu le setseng le fokolang) ho 56.01%, 'me o ne a boetse a e-na le leukemia ea tsamaiso ea methapo e bohareng.

Ka la 13 Phato, li-lymphocyte tsa autologous li ile tsa bokelloa 'me ha fanoa ka chemotherapy. Ka la 30 Phato, Mengmeng o ile a fuoa pheko ea lisele tsa CD7 CAR-T. Libeke tse peli kamora pheko, tlhahlobo ea moko oa masapo e bontšitse pholiso e felletseng, ho se nepahale ha MRD, le taolo ea leukemia ea tsamaiso ea methapo ea bohareng. O ile a ba le karabelo ea sehlopha sa 1 cytokine release syndrome (CRS) ntle le likarabelo tse mpe tsa tsamaiso ea methapo ea bohareng.